Article

BioLargo, Inc. has focused on disciplined capital deployment and long-term value creation in 2025, aligning with global investment trends in AI, energy storage, and environmental remediation. The company advanced technology platforms, emphasizing capital efficiency and technical rigor.

Initiatives in New Jersey include the Aqueous Electrostatic Concentrator installation to remove PFAS from water, a public-private collaboration for Cellinity battery factories, and Clyra Medical's expansion for medical device production set for 2026. BioLargo’s technologies aim to support industries facing water use and compliance challenges while promoting sustainable practices.

Clyra Medical is advancing with its iodine-based products, preparing for market entry, and expecting significant revenue contributions in 2026. As BioLargo enters 2026, it remains aligned with global priorities in infrastructure, energy, and health innovation, positioning itself for commercial traction.